Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04854811
Other study ID # NL74897.068.20
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date July 7, 2021
Est. completion date December 1, 2023

Study information

Verified date January 2024
Source Maastricht University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the current project is to validate the effects of chronic rolflumilast treatment (12 weeks) on cognitive functions (i.e. episodic memory) by means of behavioral tasks, in people suffering from cognitive impairments at least 1 year after stroke. Secondarily, the effects of roflumilast on daily activities and well-being will be assessed.


Description:

Rationale: In the Netherlands there are about 400.000 people who suffer from long-term consequences of a stroke. In the first months, spontaneous neurological recovery can take place, but there is hardly any functional recovery found one year after a stroke. About 40% of these patients indicate that one of the greatest problems they are facing is the impairment in cognitive functions, which also seems to be predictive for the disease outcome. Currently, the main focus of helping these patients is helping them to cope with and adapt to the new situation. There is a great medical need to actually improve cognitive functions in people that still suffer from persistent cognitive impairments one year after a stroke. Animal studies have shown that the enzyme phosphodiesterase type 4 (PDE4) plays an important role in the brain, as it has been shown to be critically linked to neuronal plasticity. Although animal studies may not always predict effects in humans, there is a strong case that PDE4 inhibition may also work in humans. Researchers from Maastricht University, and others, have shown that the PDE4 inhibitor roflumilast improved memory performance in old healthy participants and in schizophrenic patients. This is a proof of concept that PDE4 inhibition can improve memory performance in humans. A logical next step is to test if roflumilast can improve cognitive functioning and daily life activities in people suffering from cognitive problems more than one year after stroke. Objective: The objective is to validate the effects of chronic roflumilast treatment on cognitive function (i.e. episodic memory) by means of behavioral tasks, in people suffering from cognitive impairments at least 1 year after stroke. Secondary, the effects of roflumilast on daily activities and well-being will be assessed. Study design: The first phase of study will be conducted according to a double-blind, randomized placebo-controlled, between-subjects design. In a second phase, the placebo group will be given the opportunity to receive roflumilast. This is an open label design. Study population: 100 female and male, people (41-70 years old) suffering from cognitive complaints 1 year after stroke will be recruited via advertisements via social media and via local caretaking organizations (e.g., SGL, Adelante). Intervention: The study will consist of 2 arms (N = 50 per arm): placebo and 100 μg roflumilast. The duration of treatment is planned for 3 months and participants will be tested at baseline, after 1.5 months, after 3 months. The participants will also do daily computer games to stimulate their brain function. The roflumilast group will be tested 3 months treatment stopped to test if the effects last after treatment is discontinued. After the end of the 3 months-intervention period, the participants of the placebo group will be identified and they will be asked whether they would like to take roflumilast for a 3-month period. This will give information as to the roflumilast effects in an open label setting. Moreover, this gives the participants in the placebo group the opportunity to receive the active treatment (if they wish)."


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date December 1, 2023
Est. primary completion date December 1, 2023
Accepts healthy volunteers No
Gender All
Age group 41 Years to 70 Years
Eligibility Inclusion Criteria: - Willingness to sign an informed consent - Body mass index (BMI) between 18.5 and 35 - Suffered a stroke at least one year ago; and at the age of 40 or later - Objective cognitive complaint: memory performance on the delayed recall in the 15 words VWLT of below the normative score (corrected for education, sex and age) Exclusion Criteria: - Normal Pressure Hydrocephalus (NPH) - Morbus Huntington - Parkinson's disease - HIV/AIDS - Hepatitis C & B - Recent Transient Ischemic Attack (TIA) (< 1 years) - Cerebrovascular Accident (<1 years) - Chronic Obstructive Pulmonary Disease (COPD) type Gold 3 and 4 - History of schizophrenia, bipolar disorder or psychotic symptoms not otherwise specified or previous treatment for these diseases (lifetime) - Risk of suicidal behaviour - Current affective disorder (i.e. anxiety or major depression) - Cognitive problems due to alcohol abuse, brain tumor, epilepsy, encephalitis or lack of capacity to consent to participation. - Current treatment with (or illicit use of) cannabis, opiates, benzodiazepines, MDMA and cocaine - Patients with moderate or major liver impairments will be excluded (e.g. Child-Pugh B and C). - Use of medication showing strong inhibition of either CYP3A4 or CYP1A2 - Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption - Patients participating in other drug studies

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Roflumilast Oral Tablet
Once daily for 12 weeks

Locations

Country Name City State
Netherlands Maastricht University Maastricht Limburg

Sponsors (2)

Lead Sponsor Collaborator
Maastricht University Netherlands Brain Foundation

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Verbal Learning Test (VLT) Verbal Learning Test (VLT) (15 words) (delayed recall) [ Time Frame: Change from baseline to 12 weeks of chronic intake ] Verbal Learning Test (VLT) 15 words, delayed recall Change from baseline to 12 weeks of chronic intake
Secondary Verbal Learning Test (VLT) 15 words, delayed recall Change from baseline to effects one hour after the first intake (acute effects), to 6 weeks of chronic intake and to 12 weeks after the end of treatment (long-term effects)
Secondary Rivermead Behavioural Memory Test Change from baseline to effects one hour after the first intake (acute effects), to 6 weeks of chronic intake, to 12 weeks of chronic intake and to 12 weeks after the end of treatment (long-term effects)
Secondary Digit Symbol Substitution Test (DSST) Change from baseline to effects one hour after the first intake (acute effects), to 6 weeks of chronic intake, to 12 weeks of chronic intake and to 12 weeks after the end of treatment (long-term effects)
Secondary Trail Making Test (TMT) Change from baseline to effects one hour after the first intake (acute effects), to 6 weeks of chronic intake, to 12 weeks of chronic intake and to 12 weeks after the end of treatment (long-term effects)
Secondary Everyday Memory Questionnaire Change from baseline to effects one hour after the first intake (acute effects), to 6 weeks of chronic intake, to 12 weeks of chronic intake and to 12 weeks after the end of treatment (long-term effects)
Secondary the total mood score of the Hospital Anxiety and Depression Scale questionnaire (HADS) Change from baseline to effects one hour after the first intake (acute effects), to 6 weeks of chronic intake, to 12 weeks of chronic intake and to 12 weeks after the end of treatment (long-term effects)
Secondary Mood and well-being: Utrecht Scale for Evaluation of Rehabilitation-Participation (USER-Participation) (USER-P) Change from baseline to effects one hour after the first intake (acute effects), to 6 weeks of chronic intake, to 12 weeks of chronic intake and to 12 weeks after the end of treatment (long-term effects)
See also
  Status Clinical Trial Phase
Completed NCT03239847 - Cost Effectiveness of the EndoPhys Pressure Sensing Access System vs. Radial A-line for Intra-operative Blood Pressure Monitoring N/A
Recruiting NCT03544801 - Renji Cerebral Small Vessel Disease Corhort Study
Recruiting NCT06010823 - Safety and Efficacy Evaluation of the Robotic Enhanced Error Training of Upper Limb Function in Post-stroke and Post TBI Participants N/A
Withdrawn NCT04991038 - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients N/A
Recruiting NCT02472028 - Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals Phase 4
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Active, not recruiting NCT01555411 - Akershus Cardiac Examination (ACE) 1950 Study
Completed NCT01304576 - Orientation Agnosia: Clinical and Anatomical Study N/A
Completed NCT00049920 - The ARIC MRI Study N/A
Completed NCT00049894 - Predictors of Recurrent Stroke in the PROGRESS Study N/A
Completed NCT00059293 - Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
Completed NCT00005562 - Coronary Artery Calcium, Exercise Tests, and CHD Outcome N/A
Completed NCT00005395 - Honolulu Heart Program-Study of Stroke and Dementia N/A
Completed NCT00000479 - Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer Phase 3
Completed NCT00005140 - Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago N/A
Enrolling by invitation NCT00005485 - The Jackson Heart Study of Cardiovascular Disease Among African Americans
Recruiting NCT06275113 - BRING-UP Prevention
Completed NCT02702635 - Measuring Blood Flow Characteristics Using Dynamic Contrast Enhanced Magnetic Resonance Imaging N/A
Recruiting NCT04336852 - Development of a Clinically-relevant Test for Assessment of Cerebral Vascular Function N/A
Not yet recruiting NCT05892510 - Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke Phase 2/Phase 3